Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• Pixantrone is a novel aza-anthracenedione derivative.
• It exhibits cytotoxic activity against cancer cells.

Purpose of the Study:

• To evaluate the in vitro and in vivo anti-cancer efficacy of pixantrone.
• To assess pixantrone's activity against a panel of solid tumors, including Wilms tumors and sarcomas.

Main Methods:

• In vitro testing against the PPTP panel (3.0 nM to 30.0 microM).
• In vivo testing in solid tumor xenografts (7.5 mg/kg, IV, every 4 days x 3 schedule).

Main Results:

• In vitro, pixantrone showed a median relative IC50 of 54 nM.
• In vivo, pixantrone demonstrated significant differences in event-free survival (EFS) in two of eight solid tumor xenografts.
• A complete response was observed in one Wilms tumor xenograft.

Conclusions:

• Pixantrone exhibits promising cytotoxic and anti-tumor activity in preclinical models.
• Further investigation into pixantrone's therapeutic potential is warranted.